곤약 글루코만난
Konjac Glucomannan
📚 관련 논문 (19편)
1. Eur J Nutr. 2025 Oct 21;64(8):303. doi: 10.1007/s00394-025-03826-3. Effects of konjac glucomannan on gastrointestinal symptoms and gut microbiota in athletes with functional constipation: a double-blind randomized controlled trial. Zhu Y(1), Chen X(1), Song G(2). Author information: (1)Insti
2. Nutrients. 2024 Jul 10;16(14):2205. doi: 10.3390/nu16142205. Impact of Combined Prebiotic Galacto-Oligosaccharides and Bifidobacterium breve-Derived Postbiotic on Gut Microbiota and HbA1c in Prediabetic Adults: A Double-Blind, Randomized, Placebo-Controlled Study. Beteri B(1), Barone M(2), Tu
3. Int J Biol Macromol. 2023 Jan 31;226:72-76. doi: 10.1016/j.ijbiomac.2022.11.232. Epub 2022 Nov 24. Gummies candy enriched with Konjac glucomannan reduces hunger intensity and waist circumference of overweight individuals. Fernandes ACS(1), Muxfeldt L(1), Motta NG(1), Skonieski C(1), Fagundes
4. Nutrients. 2021 Jun 25;13(7):2191. doi: 10.3390/nu13072191. Konjac Glucomannan Attenuated Triglyceride Metabolism during Rice Gruel Tolerance Test. Nagasawa T(1)(2), Kimura T(1)(2)(3), Yoshida A(1)(2)(3), Tsunekawa K(1)(2)(3), Araki O(1), Ushiki K(1)(2), Ishigaki H(1), Shoho Y(1), Suda I(1)(2
5. AAPS PharmSciTech. 2026 Mar 4;27(3):129. doi: 10.1208/s12249-026-03383-w. Bi-Layered Tablets as a Novel Platform for Wound Healing and Synergistic Combination Therapy. Gattu K(#)(1), Ramirez A(#)(1), Zhu H(2), Patel K(1), Wang S(3), Cho H(4). Author information: (1)Department of Pharmaceutica
6. Biomacromolecules. 2002 May-Jun;3(3):498-504. doi: 10.1021/bm010163v. Xanthan and glucomannan mixtures: synergistic interactions and gelation. Paradossi G(1), Chiessi E, Barbiroli A, Fessas D. Author information: (1)Department of Chemical Sciences and Technologies, University of Rome Tor Verg
7. Am J Clin Nutr. 2017 May;105(5):1239-1247. doi: 10.3945/ajcn.116.142158. Epub 2017 Mar 29. A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and a
1. Trials. 2025 Oct 29;26(1):451. doi: 10.1186/s13063-025-09180-3. The effects of a newly developed beverage powder supplement on anthropometric measures, body composition, metabolic syndrome components, and appetite in obese or overweight adults: a protocol for a randomized clinical trial study. Asghari P(1), Afshari A(1), Sadeghi T(2), Jafarzadeh Esfehani A(3), Talebi S(4), Nematy M(5)(6). Author information: (1)Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. (2)School of Nursing and Midwifery, Nursing and Midwifery Care Research Center, Akbar Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. (3)Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, The University Campus (Paradise Daneshgah), Azadi Square, Mashhad, 91779-48564, Iran. (4)Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. saeedehtalebi@gmail.com. (5)Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. NematyM@mums.ac.ir. (6)Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, The University Campus (Paradise Daneshgah), Azadi Square, Mashhad, 91779-48564, Iran. NematyM@mums.ac.ir. BACKGROUND: Overweight and obesity result from excessive fat accumulation and pose significant global health challenges linked to various diseases. Recent research suggests that gut microbiota, particularly dysbiosis, is vital in obesity development. Next-generation probiotics, especially Akkermansia muciniphila, alongside compounds found in green tea extract and konjac glucomannan, offer promise in obesity management by enhancing gut microbiota balance and metabolic function. This research investigates a unique supplement that integrates these elements, proposing that it will outperform lifestyle changes alone in improving anthropometric measures, body composition, metabolic metrics, blood pressure, and appetite among overweight or obese adults. METHODS: This study will include 72 overweight or obese patients, who will be randomly assigned to either the intervention or control group within a randomized, triple-blind controlled clinical trial. The intervention group will consume 2 g of beverage sachets containing pasteurized Akkermansia muciniphila, green tea extract, and konjac glucomannan three times daily. In comparison, the control group will take 2 g of microcrystalline cellulose three times daily for 8 weeks. Evaluations of anthropometry (body mass index, waist and hip circumference), body composition (fat mass, fat-free mass, total body water, etc.), appetite using a visual analogue scale, blood pressure, and biochemical parameters including fasting blood glucose (FBS), total cholesterol (TC), triglycerides (TG), low- and high-density lipoprotein (LDL and HDL) will be conducted. DISCUSSION: The results of this study will provide evidence for the synergistic effects of Akkermansia muciniphila combined with prebiotics in the management of obesity and its associated metabolic states. TRIAL REGISTRATION: Iranian Registry of Clinical Trials (IRCT20250222064807N2) (2025/03/26). © 2025. The Author(s). DOI: 10.1186/s13063-025-09180-3 PMCID: PMC12574152 PMID: 41163054 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Ethics approval and consent to participate {24}: This study was designed in line with the national and international codes of ethics and was approved by the Ethics Committee of the Mashhad University of Medical Sciences (Code: IR.MUMS.MEDICAL.REC.1403.491). All participants will fill out a written informed consent before participation in the study. Consent for publication {32}: Not applicable. Competing interests {28}: The authors declare that they have no competing interests.
2. Eur J Nutr. 2025 Jun 9;64(5):216. doi: 10.1007/s00394-025-03732-8. Impact of a mineral enriched, fiber complex on glycaemic response and satiation in healthy adults: a double-blind, crossover intervention study. Ancu O(1), Mackenzie RWA(2), Patterson M(1), Dsilva E(3), Yakubov GE(3), Haynes M(1), Kolida S(4), Stephenson CG(4), Costabile A(5). Author information: (1)School of Life and Health Sciences, University of Roehampton, London, SW15 4 JD, UK. (2)Institute of Cardio-Metabolic Medicine, Coventry University, University Hospital Coventry & Warwick NHS Trust, Coventry, CV15 FB, UK. (3)Division of Food, Nutrition and Dietetics, School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, LE12 5RD, UK. (4)OptiBiotix Health Plc, Innovation Centre, Innovation Way, Heslington, York, Y010 5DG, UK. (5)School of Life and Health Sciences, University of Roehampton, London, SW15 4 JD, UK. adele.costabile@roehampton.ac.uk. PURPOSE: To investigate the effects of a chromium-enriched glucomannan-fructooligosaccharide complex (SB) on glycaemic and insulin responses, satiation, and hunger biomarkers in healthy adults. METHODS: Using a double-blind, placebo-controlled, randomised crossover design, we assessed the acute impact of a single 3 g SB dose in 16 healthy adults (BMI 18.5-24.9 kg/m2) during a modified oral glucose tolerance test. On separate days, participants consumed 50 g dextrose or 50 g dextrose with 3 g SB (SBD). Blood glucose and insulin were analysed over 2.5 h. Hunger, fullness, and desire to eat were assessed via visual analogue scales. Additionally, the impact of SB on gastric viscosity was assessed in vitro. RESULTS: SBD intake significantly reduced the insulin concentration compared to dextrose alone at 45, 75, and 90 min post-intake. Additionally, SBD resulted in significantly greater fullness and a lower desire to eat at 75 min when compared to dextrose (p < 0.05). Although hunger increased over time for both interventions, SBD led to lower hunger, desire to eat, and food desire scores compared to dextrose at 150 min (p < 0.05). The viscosity of SB, even when combined with dextrose, was significantly higher compared to dextrose alone. CONCLUSIONS: These novel findings suggest that SB can modulate insulin response and influence appetite regulation, highlighting its potential use in weight management strategies. © 2025. The Author(s). DOI: 10.1007/s00394-025-03732-8 PMCID: PMC12148962 PMID: 40490608 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Conflict of interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Ethics approval and consent to participate: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Ethics Committee of University of Roehampton (LSC 18/238). Informed consent was obtained from all subjects involved in the study.
3. BMC Cardiovasc Disord. 2024 Oct 9;24(1):545. doi: 10.1186/s12872-024-04223-0. The effect of glucomannan supplementation on lipid profile in adults: a GRADE-assessed systematic review and meta-analysis. Musazadeh V(#)(1)(2), Rostami RY(#)(3), Moridpour AH(4), Hosseini ZB(5), Nikpayam O(6), Falahatzadeh M(7), Faghfouri AH(8). Author information: (1)Student research committee, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. (2)Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. (3)School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran. (4)Student Research Committee, Department of Nutritional Sciences, School of Nutrition Sciences and Food Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran. (5)Faculty of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran. (6)Department of Nutritional Sciences, School of Health, Golestan University of Medical Sciences, Gorgan, Iran. (7)Department of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. maryamfalahatzade.mf@gmail.com. (8)Maternal and Childhood Obesity Research Center, Urmia University of Medical Sciences, Urmia, Iran. Amir.nut89@gmail.com. (#)Contributed equally BACKGROUND: Glucomannan has been studied for various health benefits, but its effects on lipid profile in adults are not well understood. This meta-analysis aims to evaluate the impact of glucomannan supplementation on serum/plasma levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), Apo B1, Apo A1, APO-B/ A1 ratio, and LDL-C/ HDL-C in adults. METHODS: A comprehensive search was conducted across Scopus, PubMed, Embase, and Web of Science from inception to June 2024 to identify randomized controlled trials (RCTs) assessing glucomannan supplementation on lipid profile in adults. Data were extracted and analyzed using random effects model to determine the standardized mean differences (SMDs) and 95% confidence intervals (CIs) for each biomarker. RESULTS: Glucomannan supplementation significantly decreased TC (SMD: -3.299; 95% CI: -4.955, -1.664, P < 0.001; I 2 = 95.41%, P-heterogeneity < 0.001), LDL-C (SMD: -2.993; 95% CI: -4.958, -1.028; P = 0.006; I 2 = 95.49%, P-heterogeneity < 0.001), and Apo B1 (SMD: -2.2; 95% CI: -3.58, -0.82; P = 0.01). However, glucomannan did not alter the levels of TG (SMD: -0.119; 95% CI: -1.076, 0.837, P = 0.789; I 2 = 91.63%, P-heterogeneity < 0.001), Apo A1 (SMD: -0.48; 95% CI: -6.27, 5.32; P = 0.76), APO-B/ A1 ratio (SMD: -1.15; 95% CI: -2.91, 0.61; P = 0.11), and LDL-C/ HDL-C ratio (SMD: -2.2; 95% CI: -7.28, 2.87; P = 0.2). CONCLUSIONS: Glucomannan supplementation has a beneficial effect on the level of TC and LDL-C. © 2024. The Author(s). DOI: 10.1186/s12872-024-04223-0 PMCID: PMC11465682 PMID: 39385065 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no competing interests.
4. Nutrients. 2024 Feb 17;16(4):557. doi: 10.3390/nu16040557. The Impact of Glucomannan, Inulin, and Psyllium Supplementation (Soloways(TM)) on Weight Loss in Adults with FTO, LEP, LEPR, and MC4R Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial. Pokushalov E(1)(2), Ponomarenko A(1), Garcia C(2), Pak I(1), Shrainer E(1), Seryakova M(1), Johnson M(2), Miller R(2). Author information: (1)Center for New Medical Technologies, Novosibirsk 630090, Russia. (2)Scientific Research Laboratory, Triangel Scientific, San Francisco, CA 94101, USA. This study aimed to determine the impact of a fiber supplement on body weight and composition in individuals with obesity with specific genetic polymorphisms. It involved 112 adults with obesity, each with at least one minor allele in the FTO, LEP, LEPR, or MC4R polymorphism. Participants were randomized to receive either a fiber supplement (glucomannan, inulin, and psyllium) or a placebo for 180 days. The experimental group showed significant reductions in body weight (treatment difference: -4.9%; 95% CI: -6.9% to -2.9%; p < 0.01) and BMI (treatment difference: -1.4 kg/m2; 95% CI: -1.7 to -1.2; p < 0.01) compared to placebo. Further significant decreases in fat mass (treatment difference: -13.0%; 95% CI: -14.4 to -11.7; p < 0.01) and visceral fat rating (treatment difference: -1.3; 95% CI: -1.6 to -1.0; p < 0.01) were noted. Homozygous minor allele carriers experienced greater decreases in body weight (treatment difference: -3.2%; 95% CI: -4.9% to -1.6%; p < 0.01) and BMI (treatment difference: -1.2 kg/m2; 95% CI: -2.0 to -0.4; p < 0.01) compared to heterozygous allele carriers. These carriers also had a more significant reduction in fat mass (treatment difference: -9.8%; 95% CI: -10.6 to -9.1; p < 0.01) and visceral fat rating (treatment difference: -0.9; 95% CI: -1.3 to -0.5; p < 0.01). A high incidence of gastrointestinal events was reported in the experimental group (74.6%), unlike the placebo group, which reported no side effects. Dietary supplementation with glucomannan, inulin, and psyllium effectively promotes weight loss and improves body composition in individuals with obesity, particularly those with specific genetic polymorphisms. DOI: 10.3390/nu16040557 PMCID: PMC10892568 PMID: 38398881 [Indexed for MEDLINE] Conflict of interest statement: Authors Evgeny Pokushalov, Michael Johnson, Claire Garcia and Richard Miller are employed by the company Scientific Research Laboratory, Triangel Scientific. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
5. Nutrients. 2024 Jan 12;16(2):249. doi: 10.3390/nu16020249. Effectiveness of a Food Supplement Based on Glucomannan, D-Chiro-Inositol, Cinnamomum zeylanicum Blume and Inulin in Patients with Metabolic Syndrome. Citarrella R(1), Chianetta R(1), Amodeo S(1), Mirarchi L(2), Licata A(1), Soresi M(1), Veronese N(1), Barbagallo M(1), Giannitrapani L(1)(3). Author information: (1)Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy. (2)Department of Internal Medicine, National Relevance and High Specialization Hospital Trust ARNAS Civico, Di Cristina, Benfratelli, 90127 Palermo, Italy. (3)Institute for Biomedical Research and Innovation (IRIB), National Research Council, 90146 Palermo, Italy. Metabolic syndrome (MetS) is associated with cardiovascular risk factors, such as insulin resistance, dyslipidaemia, hypertension and abdominal obesity. Given the growing need to investigate food supplements with positive health effects, this study was aimed at testing the benefits of a specific supplement for people with MetS. Fifty-eight subjects with MetS and T2DM or impaired glucose tolerance assuming metformin, were randomly assigned to take a food supplement of glucomannan, D-chiro-inositol, Cinnamomum zeylanicum blume and inulin at a daily fixed dose of 4 g orally for four months. Body weight, waist circumference, plasma lipid profile (total cholesterol, LDL, HDL and triglyc-erides), plasma glycaemic profile and visceral adiposity index (VAI) were measured at baseline and after four months of supplementation. After 16 weeks, in subjects with T2DM or insulin resistance who took the supplement (+ metformin), there was a significant reduction in body weight and BMI (p < 0.0001), serum insulin (p < 0.05) and the HOMA index (p < 0.01), as well as in the lipaemic pattern, with a significant improvement in total serum cholesterol (p < 0.005), triglycerides (p < 0.03) and LDL (p < 0.02). Our study shows that the food supplement tested is a valid and safe alternative therapeutic approach in the management of MetS and all its resulting risk factors, as its efficacy has been demonstrated across anthropometric, glucose, lipid and hepatic parameters. DOI: 10.3390/nu16020249 PMCID: PMC10819678 PMID: 38257142 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflict of interest.
6. Int J Obes (Lond). 2021 Aug;45(8):1631-1643. doi: 10.1038/s41366-021-00839-w. Epub 2021 May 11. Efficacy of dietary supplements containing isolated organic compounds for weight loss: a systematic review and meta-analysis of randomised placebo-controlled trials. Bessell E(#)(1), Maunder A(#)(2)(3), Lauche R(4)(5), Adams J(5), Sainsbury A(6), Fuller NR(2). Author information: (1)The University of Sydney, The Boden Collaboration for Obesity, Nutrition, Exercise & Eating Disorders, Charles Perkins Centre, Faculty of Medicine and Health, Sydney, NSW, Australia. erica.bessell@sydney.edu.au. (2)The University of Sydney, The Boden Collaboration for Obesity, Nutrition, Exercise & Eating Disorders, Charles Perkins Centre, Faculty of Medicine and Health, Sydney, NSW, Australia. (3)Western Sydney University, NICM Health Research Institute, Penrith, NSW, Australia. (4)Southern Cross University, National Centre for Naturopathic Medicine, Lismore, NSW, Australia. (5)University of Technology Sydney, Australian Research Centre in Complementary and Integrative Medicine (ARCCIM), School of Public Health, Faculty of Health, Sydney, NSW, Australia. (6)The University of Western Australia, School of Human Sciences, Faculty of Science, Perth, WA, Australia. (#)Contributed equally BACKGROUND/OBJECTIVES: A systematic review with meta-analysis was conducted to synthesise evidence on the efficacy of dietary supplements containing isolated organic compounds for weight loss. SUBJECTS/METHODS: Four electronic databases (Medline, Embase, Web of Science, Cinahl) were searched until December 2019. Sixty-seven randomised placebo-controlled trials of dietary supplements containing isolated organic compounds for weight loss were included. Meta-analyses were conducted for chitosan, glucomannan, conjugated linoleic acid and fructans, comparing mean weight difference post-intervention between participants receiving the dietary supplement or placebo. RESULTS: Statistically significant weight differences compared to placebo were observed for chitosan (-1.84 kg; 95% confidence interval [CI] -2.79, -0.88; p < 0.01), glucomannan (-1.27 kg; 95%CI -2.45, -0.09; p = 0.04), and conjugated linoleic acid (-1.08 kg; 95%CI -1.61, -0.55; p < 0.01). None met our threshold for clinical significance (≥2.5 kg). There was no statistically significant effect on weight for fructans compared to placebo (p = 0.24). For dietary supplements with an inadequate number of trials for meta-analysis, a statistically and borderline clinically significant weight difference compared to placebo was found for modified cellulose, manno-oligosaccharides (in males), blood orange juice extract, and three multiple-ingredient dietary supplements. These were only reported in one trial of each. Thus, more evidence is needed before recommending them for weight loss. CONCLUSIONS: While some dietary supplements containing isolated organic compounds warrant further investigation to determine efficacy and safety, there is currently insufficient evidence to recommend any of these dietary supplements for weight loss. © 2021. The Author(s), under exclusive licence to Springer Nature Limited. DOI: 10.1038/s41366-021-00839-w PMID: 33976376 [Indexed for MEDLINE]
7. J Pediatr. 2019 Aug;211:85-91.e1. doi: 10.1016/j.jpeds.2019.03.044. Epub 2019 Apr 26. No Effect of Glucomannan on Body Weight Reduction in Children and Adolescents with Overweight and Obesity: A Randomized Controlled Trial. Zalewski BM(1), Szajewska H(2). Author information: (1)Department of Paediatrics, Medical University of Warsaw, Warsaw, Poland. Electronic address: bartlomiej.zalewski@wum.edu.pl. (2)Department of Paediatrics, Medical University of Warsaw, Warsaw, Poland. OBJECTIVE: To assess the efficacy of water-soluble dietary fiber, glucomannan supplementation, on the body mass index (BMI) in children with overweight or obesity. STUDY DESIGN: In this randomized, double-blind, placebo-controlled trial, we enrolled 96 children aged 6-17 years with overweight or obesity based on the World Health Organization growth criteria (>+1 SD or >+2 SD, respectively). Participants were assigned to receive glucomannan or placebo (maltodextrin), both at a dose of 3 g/d for 12 weeks and were followed up for the next 12 weeks. Concomitant care included dietary and lifestyle advice. The primary outcome was the difference in the BMI-for-age z score change between the groups at 12 weeks. RESULTS: Compared with the placebo, glucomannan had no effect on the BMI-for-age z score at 12 weeks (mean difference: 0.0, 95% CI -0.1 to 0.1). Compared with the placebo, the glucomannan group had lower total and low-density lipoprotein cholesterol concentrations at 12 weeks. In addition, the blood pressure was greater at 12 weeks (systolic) and at 24 weeks (diastolic) in the glucomannan group. No differences between the groups in adverse events and other secondary outcomes were observed. CONCLUSIONS: Glucomannan supplementation compared with placebo had no effect on weight reduction in children with overweight and obesity. TRIAL REGISTRATION: ClinicalTrials.govNCT02280772. Copyright © 2019 Elsevier Inc. All rights reserved. DOI: 10.1016/j.jpeds.2019.03.044 PMID: 31036412 [Indexed for MEDLINE]
8. ScientificWorldJournal. 2014;2014:869250. doi: 10.1155/2014/869250. Epub 2014 Dec 9. Effects of glucomannan-enriched, aronia juice-based supplement on cellular antioxidant enzymes and membrane lipid status in subjects with abdominal obesity. Kardum N(1), Petrović-Oggiano G(1), Takic M(1), Glibetić N(1), Zec M(1), Debeljak-Martacic J(1), Konić-Ristić A(1). Author information: (1)Centre of Research Excellence in Nutrition and Metabolism, Institute for Medical Research, University of Belgrade, Drive Subotića 4, 11000 Belgrade, Serbia. The aim of this study was to analyze the effects of a 4-week-long consumption of glucomannan-enriched, aronia juice-based supplement on anthropometric parameters, membrane fatty acid profile, and status of antioxidant enzymes in erythrocytes obtained from postmenopausal women with abdominal obesity. Twenty women aged 45-65 with a mean body mass index (BMI) of 36.1 ± 4.4 kg/m(2) and waist circumference of 104.8 ± 10.1 cm were enrolled. Participants were instructed to consume 100 mL of supplement per day as part of their regular diet. A significant increase in the content of n-3 (P < 0.05) polyunsaturated fatty acids in membrane phospholipids was observed, with a marked increase in the level of docosahexaenoic fatty acid (P < 0.05). Accordingly, a decrease in the n-6 and n-3 fatty acids ratio was observed (P < 0.05). The observed effects were accompanied with an increase in glutathione peroxidase activity (P < 0.05). Values for BMI (P < 0.001), waist circumference (P < 0.001), and systolic blood pressure (P < 0.05) were significantly lower after the intervention. The obtained results indicate a positive impact of tested supplement on cellular oxidative damage, blood pressure, and anthropometric indices of obesity. DOI: 10.1155/2014/869250 PMCID: PMC4276299 PMID: 25574495 [Indexed for MEDLINE]
9. Nutr Neurosci. 2015 Feb;18(2):76-86. doi: 10.1179/1476830513Y.0000000101. Epub 2014 Jan 3. Acute effects of a dietary non-starch polysaccharide supplement on cognitive performance in healthy middle-aged adults. Best T, Howe P, Bryan J, Buckley J, Scholey A. OBJECTIVE: Certain plant polysaccharides may provide psychological health benefits. The aim of this study was to evaluate whether they can acutely improve mood and cognitive function. METHOD: In a randomized, double-blind, placebo-controlled, between subjects design trial, 73 middle-aged adults consumed 4 g of a proprietary mixture of non-starch polysaccharides (NSPs) (Ambrotose® complex), a rice flour placebo, or a sucrose control. Participants completed testing at baseline and 30 minutes post-consumption. Acute effects of consumption on mood, cognition, and blood glucose were evaluated during mental tests designed to induce mental fatigue. RESULTS: Significant improvement in recognition and working memory performance was observed in the group that consumed NSP compared with placebo or sucrose. Improvements in memory performance following NSP intake were independent of changes in blood glucose. DISCUSSION: This is the first report of acute behavioural improvement following plant polysaccharide intake in healthy middle-aged adults under conditions of mental fatigue. The findings suggest that certain NSP may enhance memory performance through mechanisms other than elevated blood glucose. DOI: 10.1179/1476830513Y.0000000101 PMID: 24621069 [Indexed for MEDLINE]
10. J Obes. 2013;2013:610908. doi: 10.1155/2013/610908. Epub 2013 Dec 30. Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults. Keithley JK(1), Swanson B(1), Mikolaitis SL(2), DeMeo M(3), Zeller JM(4), Fogg L(5), Adamji J(6). Author information: (1)Rush University College of Nursing, 600 S. Paulina Street, Suite 1080, Chicago, IL 60612, USA. (2)Rush University Medical Center, 1725 W. Harrison Street, Chicago, IL 60612, USA. (3)Section of Gastroenterology and Nutrition, Rush University Medical Center, 1725 W. Harrison Street, Chicago, IL 60612, USA. (4)North Park University School of Nursing, 3225 W. Foster Avenue, Chicago, IL 60625, USA. (5)Community, Systems, and Mental Health Nursing, Rush University College of Nursing, 600 S. Paulina Street, Suite 1080, Chicago, IL 60612, USA. (6)Faculty Practice, Rush University College of Nursing, 600 S. Paulina Street, Suite 1080, Chicago, IL 60612, USA. BACKGROUND: Few safe and effective dietary supplements are available to promote weight loss. We evaluated the safety and efficacy of glucomannan, a water-soluble fiber supplement, for achieving weight loss in overweight and moderately obese individuals consuming self-selected diets. METHODS: Participants were randomly assigned to take 1.33 grams of glucomannan or identically looking placebo capsules with 236.6 mL (8 ounces) of water one hour before breakfast, lunch, and dinner for 8 weeks. The primary efficacy outcome was change in body weight after 8 weeks. Other efficacy outcomes were changes in body composition, hunger/fullness, and lipid and glucose concentrations. Safety outcomes included gastrointestinal symptoms/tolerance and serum liver enzymes and creatinine levels. RESULTS: A total of 53 participants (18-65 years of age; BMI 25-35 kg/m²) were enrolled and randomized. The two groups did not differ with respect to baseline characteristics and compliance with the study supplement. At 8 weeks, there was no significant difference between the glucomannan and placebo groups in amount of weight loss (-.40 ± .06 and -.43 ± .07, resp.) or other efficacy outcomes or in any of the safety outcomes. CONCLUSIONS: Glucomannan supplements administered over 8 weeks were well tolerated but did not promote weight loss or significantly alter body composition, hunger/fullness, or lipid and glucose parameters. This trial is registered with NCT00613600. DOI: 10.1155/2013/610908 PMCID: PMC3892933 PMID: 24490058 [Indexed for MEDLINE]
11. Fish Shellfish Immunol. 2013 Oct;35(4):1105-10. doi: 10.1016/j.fsi.2013.07.023. Epub 2013 Jul 21. Effects of Oxidized Konjac glucomannan (OKGM) on growth and immune function of Schizothorax prenanti. Zhang L(1), Wu Y, Wang L, Wang H. Author information: (1)Institute of Animal Nutrition, Sichuan Agricultural University, Yaan, 625014 Sichuan, PR China. Schizothorax prenanti is an important existemic commercial fish in River Yangtze. OKGM (Oxidized Konjac glucomannan) is a kind of polysaccharide oxidative degraded from KGM. Added 500, 1000, 2000, 4000, 8000 mg/kg OKGM into the diets of S. prenanti. After 60 days feeding trial, WGR (weight gain rate), SGR (specific growth rate), PER (protein efficiency ratio) of groups fed the diet with 8000 mg/kg OKGM was all significantly (P < 0.05) higher; FCR (feed conversion ratio) was significantly lower than the control group whose diet have no OKGM. Hepatopancreas index, spleen index of group 6 whose feed added 8000 mg/kg OKGM were significantly higher and gallbladder index was significantly lower than the control group. Erythrocyte number, leukocyte number of group 5, 6 whose feed added 4000, 8000 mg/kg OKGM were excellent significantly (P < 0.01) more than the control group. At the same time, Erythrocyte phagocytic rate, erythrocyte phagocytic index, neutrophilic granulocyte phagocytic rate, neutrophilic granulocyte phagocytic index of all the groups whose diet added OKGM were significantly higher than the control group. Content of IgM, C3 of group 4 whose feed added 2000 mg/kg OKGM were significantly more than the control group. As for activity of CAT, group 6 was significantly higher than the control group. When compared activity of SOD, group 6 was significantly higher than group 1, 2, 3. Accordingly, activity of GSH-Px of group 3, 4, 5, 6 were significantly higher than the control group. On the contrary, content of MDA, group 3, 4, 5, 6 whose feed added 1000-8000 mg/kg OKGM was excellent significantly lower than the control group. After injected Aeromonas hydrophila 21 days, only group 6 whose feed added 8000 mg/kg OKGM survived excellent significantly more than the control group. So we can draw a conclusion of that added OKGM in the diets of S. prenanti, not only promoted growth, but also improved immune function, and the best dose was 8000 mg/kg in this experiment. Copyright © 2013 Elsevier Ltd. All rights reserved. DOI: 10.1016/j.fsi.2013.07.023 PMID: 23883580 [Indexed for MEDLINE]
12. Nutrition. 2013 Jul-Aug;29(7-8):1060-5. doi: 10.1016/j.nut.2013.02.010. Could dyslipidemic children benefit from glucomannan intake? Guardamagna O(1), Abello F, Cagliero P, Visioli F. Author information: (1)Department of Health Science and Pediatrics, University of Turin, Turin, Italy. ornella.guardamagna@unito.it OBJECTIVE: Primary dyslipidemias are major risk factors for cardiovascular disease and should be addressed early in life. The aim of this study was to evaluate, in children affected by primary hypercholesterolemia, the efficacy and tolerability of a short-term treatment with a dietary supplement containing glucomannan. METHODS: A double-blind, randomized, placebo-controlled, cross-over trial was conducted in 36 children (aged 6-15 years) affected by primary hypercholesterolemia. After a 4-week run-in period with dietary counseling, children received glucomannan or placebo twice-daily for 8 weeks, separated by a 4-week washout period. Lipid profile was assessed at baseline and after each treatment period. RESULTS: Glucomannan significantly reduced total cholesterol (TC) by 5.1% (p = 0.008), low-density lipoprotein cholesterol (LDL-C) levels by 7.3% (p = 0.008) and non-high-density lipoprotein cholesterol by 7.2% (p = 0.002) as compared with placebo. No significant differences were observed in high-density lipoprotein cholesterol, triglyceride, Apolipoprotein B, and Apolipoprotein A-I concentrations. According to sex, glucomannan significantly reduced in females, but not in males, TC (-6.1%, p = 0.011) and LDL cholesterol (-9%, p = 0.015). No major adverse effects were recorded and only few patients experienced transitory intestinal discomfort. CONCLUSION: Treatment with glucomannan of children affected by primary dyslipidemia is well-tolerated and effectively lowers total and LDL cholesterol in females and non-high-density lipoprotein cholesterol, but not Apolipoprotein B in both males and females. Copyright © 2013 Elsevier Inc. All rights reserved. DOI: 10.1016/j.nut.2013.02.010 PMID: 23759268 [Indexed for MEDLINE]
⚠️ 면책 고지
이 정보는 일반 교육 목적이며 의료 진단/처방을 대체하지 않습니다.